HBR

HBR Consulting's Annual Law Department Survey and Sounding Board Series Reveal a Year of Growth in 2022 as 2023 Challenges Loom

Retrieved on: 
Thursday, December 8, 2022
Benchmarking, HBR, Workflow, Intelligence, Outsourcing, Chung, Strategic planning, Investment, Growth, Thought, Work, State Department Sounding Board, Traction, Risk, Retail, Sales, Renewable energy, Management, Survey, Sounding board

CHICAGO, Dec. 8, 2022 /PRNewswire/ -- While the majority of law departments anticipated increases in headcount, spending, and investments in technology throughout most of 2022, heading into the new year law department leaders anticipate economic pressures and evolving demand will impact their focus in 2023, according to the 2022 HBR Consulting (HBR) Law Department Survey and HBR's series of law department Sounding Boards held throughout 2022.

Key Points: 
  • "This year's Survey results and Sounding Board data provide interesting insights on how the macro-economic realities are impacting law departments, intensifying focus on the upcoming law firm rate review cycle.
  • Through Q3 2022, the majority of law departments continued to maintain favorable hiring outlooks, projected spend increases, and growth in demand.
  • The annual HBR Law Department Survey is the leading source of benchmarking data for corporate law departments, providing comprehensive data on legal spending, staffing, operations, technology, outside counsel management and compensation.
  • The 2022 HBR Sounding Board Series brought together a range of law department and law firm leaders in meetings with their peers.

Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference

Retrieved on: 
Tuesday, November 22, 2022
GSK, Infection, Degenerative disease, Conference, Bacteria, Therapy, Patient, Cutis verticis gyrata, HBR, Pyelonephritis, Research, MDR, FDA, Tebipenem, Pharmaceutical industry, Spero

A replay of the fireside chat will be available on the website following the conclusion of the event.

Key Points: 
  • A replay of the fireside chat will be available on the website following the conclusion of the event.
  • Spero Therapeutics, headquartered in Cambridge, Massachusetts,is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases.
  • Spero Therapeuticsis developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.
  • However, while Spero may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Harvard Business Review Commemorates 100th Anniversary

Retrieved on: 
Tuesday, November 22, 2022
Banking, Accounting, Professional Services, Blogging, Other Communications, Publishing, Public Relations, Investor Relations, Marketing, Continuing, Advertising, University, Communications, Education, Insurance, Human Resources, Finance, Consulting, Marketing, Invention, Emotional intelligence, Global Peter Drucker Forum, Harvard Business Review, HBR, Theodore Levitt, Capitalism, Economic Insights, Multimedia, Research, Blue Ocean Strategy, Harvard Business School, Ascend, Organization, Climate change, History, Book, Management

With its focus on actionable business ideas for leaders, HBR occupies a unique position in business media, blending research and insights written by academics, thought leaders, and practitioners.

Key Points: 
  • With its focus on actionable business ideas for leaders, HBR occupies a unique position in business media, blending research and insights written by academics, thought leaders, and practitioners.
  • As Harvard Business Review enters its second century, one thing will remain steadfast: our commitment to helping leaders solve the worlds toughest management challenges, said HBR Editor in Chief Adi Ignatius.
  • Harvard Business Review is the leading destination for smart management thinking.
  • Through its flagship magazine, 10 international licensed editions, books from Harvard Business Review Press, and digital content and tools published on HBR.org , Harvard Business Review provides professionals around the world with rigorous insights and best practices to lead themselves and their organizations more effectively and to make a positive impact.

HBR Consulting Fuels Continued Growth by Attracting Strategic Investment in Advisory Business from Renovus Capital

Retrieved on: 
Tuesday, November 15, 2022
Information technology, Growth, Quil Ceda Village, Movement, Technology, The National Law Journal, Information technology consulting, Environment, HBR, Knowledge, Risk management, Organization, Partnership, Industry, Managed services, Education, Investment, Culture, CEO, Private law, Risk, Review, System, LAC Group, Retail, Financial services, Management, LinkedIn

CHICAGO, Nov. 15, 2022 /PRNewswire/ -- HBR Consulting (HBR), the legal industry's leading strategy, operations and technology consulting firm, is pleased to announce an agreement with private equity firm Renovus Capital (Renovus) as a strategic capital partner to acquire HBR's Advisory business, effective November 10, 2022.

Key Points: 
  • Strategic partnership secures HBR's position as leading legal advisory firm amid industry's accelerated service delivery, tech evolution
    CHICAGO, Nov. 15, 2022 /PRNewswire/ -- HBR Consulting (HBR), the legal industry's leading strategy, operations and technology consulting firm, is pleased to announce an agreement with private equity firm Renovus Capital (Renovus) as a strategic capital partner to acquire HBR's Advisory business, effective November 10, 2022.
  • In conjunction with the investment, HBR's Advisory business will separate and operate independently from the Information Technology (IT), Managed Services and Keno Kozie businesses.
  • HBR's established leadership team will reorganize accordingly, forming a new executive leadership team for HBR Consulting with a combined 50 years with HBR, including Matt Sunderman , the current president of HBR's Advisory business, who will assume the role of HBR Consulting chief executive officer.
  • This growth investment will propel the HBR Consulting business forward to meet the industry's increasingly pronounced strategic and operational needs."

Hydrogen Bromide Market Report 2022: Favorable Regulations on the Use of Bromine Helping Boost Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, November 11, 2022
Chemicals, Plastics, Manufacturing, Hydrogen, Pulmonary edema, Photography, Mouth, Laryngospasm, Industry, Stomach, Electronics, Agriculture, HBR, Phosphorus, Bromine, Calcium, CAGR, Computer, Dermatitis, Aerosol, Growth, Sodium, Refrigeration, Holography, Inhalation, Lithium

The "Hydrogen Bromide Market By Type, By End-use Industry: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hydrogen Bromide Market By Type, By End-use Industry: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
  • The global hydrogen bromide market is expected to increase in the near future due to favorable regulations on the use of bromine, due to its harmless nature in the atmosphere.
  • Hydrogen bromide finds its application in oil and gas drilling operations, and the growing oil and gas industry is expected to further drive the global hydrogen bromide market growth.
  • Due to the recent global chip shortage, there is a wide spectrum of opportunities for expansion of the hydrogen bromide market.

CHIMEI to Launch Ecologue(TM) Bio-ABS Products with ISCC PLUS Approval in 2023

Retrieved on: 
Thursday, November 10, 2022
Carbon, ISCC, Mitsubishi Corporation, Recycling, HBR, PCR, Neste, International Sustainability Alliance, ABS, PLUS, SSBR, Efficiency, Rubber industry in Malaysia, MMA, Bioplastic, Chi, Plastic, News, MS, Fossil fuel, Amusement arcade, Renewable energy, SAN

CHIMEI Corporation's factory in Tainan, Taiwan, has obtained International Sustainability and Carbon Certification (ISCC) PLUS for ABS, SAN, MS (SMMA), HBR, and SSBR products.

Key Points: 
  • CHIMEI is preparing to replace some of the fossil feedstock used in its polymer production with bio-based feedstock.
  • The ISCC PLUS approvals apply to ABS, SAN, MS (SMMA), HBR, and SSBR products, which are produced at CHIMEI's factory in Tainan, Taiwan.
  • CHIMEI will officially launch ISCC PLUS bio-ABS products, under the Ecologue trademark, in the first half of 2023.
  • CHIMEI Corporation first received the ISCC PLUS approvals during K 2022, the world-leading trade fair for plastics and rubber.

Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr

Retrieved on: 
Tuesday, November 8, 2022
GLOBE, Adult, Cutis verticis gyrata, Infection, Pyelonephritis, Tebipenem, Nasdaq, MDR, Research, Therapy, U.S. Securities and Exchange Commission, No, GSK, HBR, Degenerative disease, Patient, Bacteria, Urinary tract infection, FDA, Limited, Pharmaceutical industry, Vaccine, Spero, Meiji Seika

3) Limited (LSE/NYSE: GSK) (GSK) for tebipenem HBr, an investigational drug being developed as the potentially first oral carbapenem antibiotic for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain bacteria.

Key Points: 
  • 3) Limited (LSE/NYSE: GSK) (GSK) for tebipenem HBr, an investigational drug being developed as the potentially first oral carbapenem antibiotic for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain bacteria.
  • In exchange, GSK has been granted an exclusive license to develop and commercialize tebipenem pivoxil and tebipenem pivoxil HBr in all territories, except Japan, and certain other Asian countries, territories which will be retained by Spero partner, Meiji Seika.
  • Under the terms of the license agreement, Spero is responsible for the execution and costs of a follow-up Phase 3 clinical trial of tebipenem HBr.
  • GSK is responsible for the execution and costs of additional development, including Phase 3 regulatory filing and commercialization activities for tebipenem HBr outside of the Meiji Seika territory.

Life Sciences C-Suite Leaders To Explore "Reinventing Life Sciences Leadership" at January Vanguard Forum in Cambridge

Retrieved on: 
Wednesday, November 9, 2022
Industry, Chief executive officer, Technology, The Vanguard Group, Schering-Plough, NEW, Economics, Vanguard, Forum, GC, Leadership, Perception, HBR, Management, Tenneco, United Airlines, Walgreens

NEW YORK, Nov. 9, 2022 /PRNewswire-PRWeb/ -- The Vanguard Network today announced its annual Life Sciences leadership Forum on January 23 in Cambridge, MA. The event marks a return to face-to-face Vanguard events for C-Suite life sciences and healthcare leaders.

Key Points: 
  • Life Sciences leaders to gather in Cambridge, MA for a confidential, highly-interactive looks at the future of the industry.
  • NEW YORK, Nov. 9, 2022 /PRNewswire-PRWeb/ -- The Vanguard Network today announced its annual Life Sciences leadership Forum on January 23 in Cambridge, MA.
  • The event marks a return to face-to-face Vanguard events for C-Suite life sciences and healthcare leaders.
  • The day-long Forum includes confidential, highly interactive sessions designed to reflect the real-life challenges facing today's life sciences executives.

Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

Retrieved on: 
Monday, November 7, 2022
Cutis verticis gyrata, Company, HBR, MDR, GLOBE, FDA, Adult, Infection, Therapy, Nasdaq, Pyelonephritis, Bacteria, Degenerative disease, ID, Spero, Patient, Tebipenem, Pharmaceutical industry

ET to report its third quarter 2022 financial results and provide an update on its business and pipeline.

Key Points: 
  • ET to report its third quarter 2022 financial results and provide an update on its business and pipeline.
  • To access the call, please dial 1-855-327-6837 (domestic) or 1-631-891-4304 (international) and refer to conference ID 10020538.
  • The audio webcast can be accessed under "Events and Presentations" in the Investor and Media section of the Company's website at www.sperotherapeutics.com .
  • Spero Therapeuticsis developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.

Axiom Acquires Plexus's Flexible Legal Talent Division Plexus Engage

Retrieved on: 
Monday, November 7, 2022
NEW, General Motors, Growth, Education, Compliance, Woolworth, RBC, Intellectual property, Publication, Plexus, Transport, Time, Lawyer, Employment, Fortune 500, Private law, L'Oréal, Coca-Cola, HBR, Acquisition, Technology, Insurance, Workload, Gartner, Software, Financial Times, Efficiency, Property management, Construction, Axiom, Australia Post

MELBOURNE, Australia and NEW YORK, Nov. 6, 2022 /PRNewswire/ -- Axiom, the global leader in high-caliber, on-demand legal talent, announced it has acquired Plexus Engage, a subsidiary of Australian headquartered legal technology company Plexus. Plexus Engage offers highly experienced, flexible lawyers for in-house legal teams to support projects or augment capacity. This acquisition further advances Axiom's long-term M&A and geographic expansion plans, providing an entry into Australia and enhancing Axiom's footprint in the APAC region, while allowing Plexus to focus on scaling its award-winning legal operating system for in-house counsel. Plexus Engage General Manager, Richard Kohinga, will continue to lead the organization as a wholly owned subsidiary of Axiom, operating as Axiom Global Australia. Terms of the deal will not be disclosed.  

Key Points: 
  • MELBOURNE, Australia and NEW YORK, Nov. 6, 2022 /PRNewswire/ -- Axiom , the global leader in high-caliber, on-demand legal talent, announced it has acquired Plexus Engage, a subsidiary of Australian headquartered legal technology company Plexus.
  • Plexus Engage offers highly experienced, flexible lawyers for in-house legal teams to support projects or augment capacity.
  • "Plexus Engage provides Axiom with an experienced team with a proven track record of driving both growth and profitability in the Australian market," said David McVeigh, Chief Executive Officer of Axiom.
  • Axiom is where legal teams go to find the right talent for everything from ongoing in-house matters to complex outside counsel work.